SK Biopharmaceuticals, Co., Ltd., a biotech company operating on research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and oncology worldwide, unveiled the establishment of Mentis Care, Inc., a joint venture with a leading Brazil-based pharmaceutical company, Eurofarma, with presence in 24 countries, including North America, Latin America and Africa, to commercialize an AI-based epilepsy monitoring platform.
The company organized a launching ceremony on October 20 (EDT) in Toronto, Canada, to celebrate its full-scale expansion into digital healthcare beyond its innovative drug development portfolio.
The company plans to expand its local team, strengthen academic and industry collaborations, and pursue clinical validation of its AI algorithms.
SK Life Science, Inc., with headquarters in Paramus, New Jersey, is a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., a prominent pioneering South Korean company in drug discovery & commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with eight compounds currently in development.
Executive Statement
According to Hassan Kotob, CEO of Mentis Care, Mentis Care is an AI-driven digital health company with the mission to help patients with epilepsy live safer and more independently through AI-powered seizure prediction and monitoring. By combining the innovation capabilities of their partners, SK Biopharmaceuticals and Eurofarma, they aim to establish a new standard in digital epilepsy management for patients worldwide.
